201 related articles for article (PubMed ID: 9848118)
1. Subchronic toxicity of human immunodeficiency virus and tuberculosis combination therapies in B6C3F1 mice.
Rao GN; Lindamood C; Heath JE; Farnell DR; Giles HD
Toxicol Sci; 1998 Sep; 45(1):113-27. PubMed ID: 9848118
[TBL] [Abstract][Full Text] [Related]
2. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
[TBL] [Abstract][Full Text] [Related]
3. The human immunodeficiency virus type 1 Tat protein potentiates zidovudine-induced cellular toxicity in transgenic mice.
Prakash O; Teng S; Ali M; Zhu X; Coleman R; Dabdoub RA; Chambers R; Aw TY; Flores SC; Joshi BH
Arch Biochem Biophys; 1997 Jul; 343(2):173-80. PubMed ID: 9224727
[TBL] [Abstract][Full Text] [Related]
4. Genetic damage detected in CD-1 mouse pups exposed perinatally to 3'-azido-3'-deoxythymidine or dideoxyinosine via maternal dosing, nursing, and direct gavage: II. Effects of the individual agents compared to combination treatment.
Witt KL; Tice RR; Wolfe GW; Bishop JB
Environ Mol Mutagen; 2004; 44(4):321-8. PubMed ID: 15476197
[TBL] [Abstract][Full Text] [Related]
5. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
[TBL] [Abstract][Full Text] [Related]
6. Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination.
Chan SS; Santos JH; Meyer JN; Mandavilli BS; Cook DL; McCash CL; Kissling GE; Nyska A; Foley JF; van Houten B; Copeland WC; Walker VE; Witt KL; Bishop JB
Environ Mol Mutagen; 2007; 48(3-4):190-200. PubMed ID: 16395692
[TBL] [Abstract][Full Text] [Related]
7. [Acute toxic action of combinations of antibiotics with isoniazid].
Ziia AV; Sokolova GB; Lebedeva MN
Antibiotiki; 1982; 27(7):535-9. PubMed ID: 7137978
[TBL] [Abstract][Full Text] [Related]
8. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
9. Terminalia chebula (fruit) prevents liver toxicity caused by sub-chronic administration of rifampicin, isoniazid and pyrazinamide in combination.
Tasduq SA; Singh K; Satti NK; Gupta DK; Suri KA; Johri RK
Hum Exp Toxicol; 2006 Mar; 25(3):111-8. PubMed ID: 16634329
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hematopoietic progenitor cell proliferation by ethanol in human immunodeficiency virus type 1 tat-expressing transgenic mice.
Prakash O; Rodriguez VE; Tang ZY; Zhou P; Coleman R; Dhillon G; Shellito JE; Nelson S
Alcohol Clin Exp Res; 2001 Mar; 25(3):450-6. PubMed ID: 11290858
[TBL] [Abstract][Full Text] [Related]
11. [Comparative characterization of the hepatotoxicity of isoniazid, rifampicin and pyrazinamide].
Slivka IuI
Farmakol Toksikol; 1989; 52(4):82-5. PubMed ID: 2806536
[TBL] [Abstract][Full Text] [Related]
12. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
[TBL] [Abstract][Full Text] [Related]
14. In vivo toxicity of foscarnet and zidovudine given alone or in combination.
Omar RF; Gourde P; Désormeaux A; Tremblay M; Beauchamp D; Bergeron MG
Toxicol Appl Pharmacol; 1996 Aug; 139(2):324-32. PubMed ID: 8806849
[TBL] [Abstract][Full Text] [Related]
15. Transplacental drug transfer and frequency of Tk and Hprt lymphocyte mutants and peripheral blood micronuclei in mice treated transplacentally with zidovudine and lamivudine.
Von Tungeln LS; Williams LD; Doerge DR; Shaddock JG; McGarrity LJ; Morris SM; Mittelstaedt RA; Heflich RH; Beland FA
Environ Mol Mutagen; 2007; 48(3-4):258-69. PubMed ID: 16850453
[TBL] [Abstract][Full Text] [Related]
16. The effect of rifampicin and pyrazinamide on isoniazid pharmacokinetics in rats.
Baldan HM; De Rosa HJ; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Nov; 28(8):409-13. PubMed ID: 17828712
[TBL] [Abstract][Full Text] [Related]
17. Acute toxic effects of 3'-azido-3'-deoxythymidine (AZT) on normal and regenerating murine hematopoiesis.
Scheding S; Media JE; Nakeff A
Exp Hematol; 1994 Jan; 22(1):60-5. PubMed ID: 8282060
[TBL] [Abstract][Full Text] [Related]
18. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
